论文部分内容阅读
目的评价泛昔洛韦联合1%氢化可的松乳膏治疗单纯疱疹的疗效及安全性。方法 74例单纯疱疹患者随机分成两组,治疗组(38例)予口服泛昔洛韦500mg,同时予1%氢化可的松乳膏外搽,均3次/d,连用5d;对照组(36例)仅予泛昔洛韦口服联合赋形剂治疗。结果用药后第7和10d时,治疗组的痊愈率为78.95%和89.47%,对照组为55.56%和69.44%;治疗组有效率为86.84%和97.37%,对照组为66.67%和77.78%;治疗组平均止疱时间、开始结痂时间、全部结痂时间、症状消失时间和治愈平均时间分别为(1.3±1.1)d,(2.3±1.4)d,(3.6±1.6)d,(3.7±1.5)d和(5.6±1.7)d;对照组依次为(1.9±1.2)d,(3.0±1.5)d,(4.5±1.6)d,(4.7±1.7)d和(6.6±1.6)d。治疗组均优于对照组,差异均有统计学意义(P均<0.05)。两组均无严重不良反应发生。结论局部应用糖皮质激素联合抗病毒药物治疗单纯疱疹安全有效。但还需要更多的临床试验来证实。
Objective To evaluate the efficacy and safety of famciclovir plus 1% hydrocortisone cream in the treatment of herpes simplex. Methods 74 patients with herpes simplex were randomly divided into two groups. The treatment group (38 cases) received famciclovir 500 mg orally and 1% hydrocortisone cream ointment for 3 d / d for 5 days respectively. The control group (36 cases) Only famciclovir oral co-excipient treatment. Results The cure rates were 78.95% and 89.47% in the treatment group and 55.56% and 69.44% in the control group on the 7th and 10th day after treatment. The effective rates in the treatment group were 86.84% and 97.37%, while those in the control group were 66.67% and 77.78%, respectively. The average blister time, initial scabbing time, total scabbing time, symptom disappearance time and the average time to cure in the treatment group were (1.3 ± 1.1) days, (2.3 ± 1.4 days), (3.6 ± 1.6 days) and (3.7 ± 1.5 d and 5.6 ± 1.7 d, respectively. The control group was (1.9 ± 1.2) d, (3.0 ± 1.5) d, (4.5 ± 1.6) d, (4.7 ± 1.7) d and (6.6 ± 1.6) d respectively. The treatment group were better than the control group, the differences were statistically significant (P all <0.05). No serious adverse reactions occurred in both groups. Conclusion Local application of glucocorticoid combined with antiviral drugs in the treatment of herpes simplex is safe and effective. But more clinical trials are needed to confirm this.